PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG

NCT06567795 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 189

Last updated 2024-08-23

No results posted yet for this study

Summary

To evaluate the proportion of diabetic mellitus patients with CV events as measured by HEMOTAG.

Conditions

Interventions

DEVICE

Hemotag

Hemotag non-invasive medical device is used to see cardiac function for DM2 patients at-home for 30 days

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH
  • Aventusoft, LLC.

    lead INDUSTRY

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-14
Primary Completion
2026-03-18
Completion
2027-03-18
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06567795 on ClinicalTrials.gov